Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2015 Sep 1.

Published in final edited form as: J Neurochem. 2014 Apr 19;130(5):642–656. doi: 10.1111/jnc.12724

Fig. 3 — HIV-1 Tat-induced potentiation of NMDA-evoked increases in [Ca²⁺]_i is reversible. A-D, representative traces show NMDA-evoked [Ca²⁺]_i increases from control neurons or neurons treated with 50 ng/mLTat for the times indicated above the traces. NMDA (10 μM × 30 s) was applied by superfusion at the times indicated by the horizontal bars. Cells were pretreated with 50 nM RAP or 10 μM PP2 1 h prior to superfusion with 10 μM NMDA as indicated. E-H, Bar graph shows net [Ca²⁺]_i increase evoked by 10 μM NMDA in control cells or cells treated with Tat . Cells were pretreated for 1 h with 50nM RAP or 10 μM PP2 as indicated. **p<0.01, ****p<0.0001 relative to respective control; #p<0.05, ####p<0.0001 relative to Tat alone as determined by separate, one-way ANOVAs with 6 levels for each treatment time followed by Tukey's post-test for multiple comparisons.

Inline graphic — HIV-1 Tat-induced potentiation of NMDA-evoked increases in [Ca²⁺]_i is reversible. A-D, representative traces show NMDA-evoked [Ca²⁺]_i increases from control neurons or neurons treated with 50 ng/mLTat for the times indicated above the traces. NMDA (10 μM × 30 s) was applied by superfusion at the times indicated by the horizontal bars. Cells were pretreated with 50 nM RAP or 10 μM PP2 1 h prior to superfusion with 10 μM NMDA as indicated. E-H, Bar graph shows net [Ca²⁺]_i increase evoked by 10 μM NMDA in control cells or cells treated with Tat . Cells were pretreated for 1 h with 50nM RAP or 10 μM PP2 as indicated. **p<0.01, ****p<0.0001 relative to respective control; #p<0.05, ####p<0.0001 relative to Tat alone as determined by separate, one-way ANOVAs with 6 levels for each treatment time followed by Tukey's post-test for multiple comparisons.